Compare Ginkgo Bioworks Holdings Inc (DNA) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Invesco NASDAQ 100 ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Invesco NASDAQ 100 ETF trades at $309.39 (market cap $113.40B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 148.5× Ginkgo Bioworks Holdings Inc's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| DNA | QQQM | |
|---|---|---|
Market Cap | $763.64M | $113.40B |
Volume | 3,204,177 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $15.83 | $312.76 |
52-Week Low | $5.48 | $229.87 |
Typical Hold Time | 7 Days | 54 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
QQQM trades at $307.85, down 1.33% today, while maintaining a bullish technical outlook with strong moving average support. The Invesco NASDAQ 100 ETF continues to benefit from institutional accumulation, with QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show the ETF trading near key resistance at $309, with support established at $305 and $303 levels. The fund's 0.15% expense ratio provides a cost advantage over similar NASDAQ-100 tracking products.
QQQM offers efficient exposure to NASDAQ-100 growth stocks with lower fees, though concentration in technology sectors presents volatility risks. Institutional buying signals confidence in the ETF's long-term prospects despite recent market fluctuations. Investors should monitor technology sector performance and interest rate sensitivity as key drivers of future returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
